Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LON peptidase N-terminal domain and RING finger protein 2 (LONRF2) is a protein-coding gene in humans and other vertebrates encoding an enzyme that contains both a peptidase domain related to protein quality control and a RING finger domain implicated in ubiquitin ligase activity[2][4][8]. It is predicted to participate in the ubiquitination and degradation of misfolded or damaged proteins, contributing to cellular protein quality control pathways[2][5][8]. LONRF2 is localized to the cytoplasm and has been associated with ATP-dependent peptidase and ubiquitin protein ligase activities[2][5]. Disorders linked to LONRF2 include Immunodeficiency 15B and childhood germ cell cancer, though specific disease mechanisms have not yet been fully elucidated[2]. No approved drugs or strong biomarker roles have been identified for LONRF2, though its enzymatic function underlies potential therapeutic targeting in disease states characterized by protein misfolding or abnormal ubiquitination[2][5][8].
Ubiquitin ligase activity (potential mechanism for any targeted therapeutic modulation); Proteostasis regulation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LON peptidase N-terminal domain and RING finger protein 2 (LONRF2).